Hard to Treat Diseases Inc.
Limited financial coverage for HTDS.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
About the company
Hard to Treat Diseases Inc. (HTDS), founded in 2009 and headquartered in Shenzhen, China, is a pharmaceutical firm engaged in the development, manufacturing, and global export of biopharmaceutical products and vaccines. The company's extensive portfolio includes a range of biological agents such as reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection.
- CEO
- Shimin Yuan
- IPO
- 1998
- HQ
- Shenzhen, CN
Price Chart
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.77
- Avg Volume
- 233.42K
Get TickerSpark's AI analysis on HTDS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HTDS coverage
Recent articles, reports, and earnings notes.
No research on HTDS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HTDS report →Similar companies
Peers in the same neighborhood.